| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Men |
| Source | KevinMD |
| URL | kevinmd.com/2026/01/low-testosterone-in-men-a-doctors-guide-to-trt-safety.html (opens in a new tab) |
Specific Claim Evaluated
Guidelines list untreated prostate or breast cancer and severe heart failure as contraindications, a hematocrit above about 48 to 50% is a relative reason to avoid or delay therapy, and testosterone is not appropriate for men actively trying to conceive.
Primary Research Supporting or Contradicting the Claim
The Endocrine Society guideline recommends against testosterone therapy in men planning fertility in the near term, in men with prostate or breast cancer, elevated hematocrit or uncontrolled heart failure, and recommends baseline and on-treatment hematocrit monitoring (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
The article is correct. Pretreatment assessment should include prostate cancer risk, hematocrit and fertility plans.
Rationale for Grade
The contraindications, hematocrit threshold and fertility advice are consistent with the guideline. The article does not discuss cardiovascular trial data, but it makes no cardiovascular claim, so the omission does not affect the accuracy of what is stated.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs"